TG Therapeutics (TGTX) Moves 17.7% Higher: Will This Strength Last?Zacks Investment Research • 01/31/22
SHAREHOLDER ALERT: Investigation of TG Therapeutics, Inc. (TGTX) Announced by Holzer & Holzer, LLCNewsfile Corp • 01/27/22
TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold On Blood Cancer TrialsBenzinga • 01/27/22
TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor ConferenceGlobeNewsWire • 01/24/22
Are These 7 of the Worst-Performing Stocks of 2021 Ready to Skyrocket This Year?The Motley Fool • 01/22/22
TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/22
TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 MillionGlobeNewsWire • 01/04/22
TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/14/21
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple SclerosisGlobeNewsWire • 12/14/21
TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/13/21
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/10/21
TG THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TG Therapeutics, Inc. on Behalf of TG Therapeutics Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 12/04/21
SHAREHOLDER ALERT: Investigation of TG Therapeutics, Inc. Announced by Holzer & Holzer, LLCNewsfile Corp • 12/01/21
TG Therapeutics Shares Plunge After FDA Plans AdComm Meet For Blood Cancer CandidateBenzinga • 11/30/21